Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

• Váldodahkkit: Laura Jimbu (Dahkki), Oana Mesaros (Dahkki), Cristian Popescu (Dahkki), Alexandra Neaga (Dahkki), Iulia Berceanu (Dahkki), Delia Dima (Dahkki), Mihaela Gaman (Dahkki), Mihnea Zdrenghea (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2021-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...